Internationellt pressmeddelande:
Organon and Pfizer discontinue their collaboration on asenapine
(New York, New York, USA and Arnhem, The Netherlands): Organon and Pfizer today announced that they have agreed to discontinue their collaboration in the further development of asenapine, a new drug candidate for the treatment of schizophrenia and acute mania associated with Bipolar I Disorder.
Pfizer’s decision to discontinue its participation in the asenapine development program is an outcome of a commercial analysis of the compound as a part of its overall portfolio. Pfizer will return all product rights, intellectual property and data to Organon and make orderly transitions during 2007.
Organon will continue to develop asenapine.
För ytterligare information
Mrs. Monique Mols
Information avsedd för journalister.
